Table 1. Baseline characteristics.
| Characteristics | All patients (N=34) |
|---|---|
| Follow-up, median [range], months | 12 [3–20] |
| Age, year | |
| Median [range] | 68 [37–84] |
| Sex, No. (%) | |
| Male | 21 (53.8) |
| Female | 13 (33.3) |
| Race, No. (%) | |
| White | 24 (61.5) |
| Black or African-American | 8 (20.5) |
| Asian | 1 (2.6) |
| Unknown | 1 (2.6) |
| Stage, No. (%) | |
| IIIA | 20 (51.3) |
| IIIB | 11 (28.2) |
| IIIC | 1 (2.6) |
| Other† | 2 (5.1) |
| ECOG Performance Status Score (%) | |
| 0 | 10 (25.6) |
| 1 | 19 (48.7) |
| 2 | 5 (12.8) |
| Histology, No. (%) | |
| Adenocarcinoma | 15 (38.5) |
| Squamous | 12 (30.8) |
| Non-small cell, NOS | 7 (17.9) |
| Smoking status, No. (%) | |
| Current smoker | 7 (17.9) |
| Former smoker | 25 (64.1) |
| Never smoker | 2 (5.1) |
| Charlson/Deyo comorbidity score (%) | |
| 0 | 7 (20.6%) |
| 1 | 9 (26.5%) |
| 2 | 6 (17.6%) |
| ≥3 | 12 (35.3%) |
| Concurrent chemotherapy, No. (%) | |
| Carboplatin/paclitaxel | 30 (76.9) |
| Cisplatin/etoposide | 3 (7.7) |
| Other‡ | 1 (2.6) |
| Radiation dose/fractionation, Gy/fractions | |
| Median (range) | 60 [60–70]/30 [30–35] |
| Radiation modality, No. (%) | |
| IMRT | 30 (76.9%) |
| Protons | 4 (10.3%) |
†, ‘other’ stage included 1 patient with stage IIB and 1 patient with recurrent stage IIIB; ‡, ‘other’ concurrent chemotherapy included 1 patient receiving carboplatin/etoposide, percentages may not total 100 because of rounding. ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified.